BioCentury
ARTICLE | Clinical News

Pollinex Quattro Grass: Additional Phase III data

June 16, 2008 7:00 AM UTC

Allergy Therapeutics reported additional data from the double-blind, U.S., Canadian and European Phase III G301 trial in 1,028 patients. In patients with severe seasonal allergic rhino-conjunctivitis ...